10% of Cystic Fibrosis Patients Still Await Effective Treatment
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowApproximately 10% of cystic fibrosis patients do not benefit from recent advancements in CF treatments, which use drugs like Trikafta. These drugs, made by Vertex Pharmaceuticals, enhance the CFTR protein function for 90% of patients, transforming the disease into a more manageable condition. However, the remaining 10% of patients, born with other genetic mutations, experience a lack of effective treatment. Recent scientific efforts, including attempts by Vertex and Moderna using mRNA technology and Boehringer Ingelheim's gene therapy trials, were halted due to tolerability issues and other challenges.
Emily's Entourage, a nonprofit founded by Emily Kramer-Golinkoff, has played a key role in continuing research for these patients. Since its inception in 2011, it has raised over $22 million, funding 51 research projects that explore novel treatments like antisense oligonucleotides and small molecules. Delivering drugs to affected lung cells poses significant scientific challenges because of the lungs' natural defenses and the presence of thick mucus in CF patients.
This matters to ordinary investors as ongoing research might open opportunities for pharmaceutical companies to address the unmet needs of these patients, potentially leading to breakthroughs that could impact company valuations and future investment decisions.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Our take
Opinion from the Newsstocks AI desk, not investment adviceIn our view, the research gap for 10% of cystic fibrosis patients creates room for innovation in the pharmaceutical industry. While recent clinical trial challenges have posed setbacks, sustained research efforts and funding initiatives, like those by Emily's Entourage, are vital. These developments could eventually influence pharmaceutical valuations once effective treatments are realized.
Key numbers
- Percentage of patients benefiting
- 90%
- Research funding raised
- $22 million
What could help
- Significant funding could accelerate research for effective treatments.
What could hurt
- Past clinical trials have faced significant challenges, delaying breakthroughs.
What to watch next
The cystic fibrosis community will gather in Atlanta this week, focusing on treatments for the unmet needs of 10% of patients.
The background
Cystic fibrosis is a genetic disorder causing lung infections and mucus buildup. Advances in treatment have helped many, but not all patients.
Questions readers ask
Why do some cystic fibrosis patients not benefit from current drugs?
Current CF drugs like Trikafta work for those with specific genetic mutations, leaving about 10% without effective treatment due to different genetic factors.
What is Emily's Entourage?
Emily's Entourage is a nonprofit founded in 2011 to speed up research for cystic fibrosis patients who don't respond to current treatments, raising over $22 million.
What challenges do drug trials for cystic fibrosis face?
Delivering treatments to lung cells is challenging due to the lungs' defenses and mucus buildup in CF patients, leading to trial obstacles.
About CF Industries Holdings (CF)
CF Industries is a leading producer of nitrogen fertilizer.
The Materials sector covers chemical, metal, mining and packaging companies that supply raw inputs.
Earlier CF news
CF stock page and all news →Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
